Advertisement Boehringer invests €100m to increase Respimat production in Dortmund - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Boehringer invests €100m to increase Respimat production in Dortmund

German research-driven pharmaceutical firm Boehringer Ingelheim is investing more than €100m at its Dortmund site to increase the production capacity of Respimat inhaler to 44 million units per year.

Respimat-Produktion

The expansion is expected to help the pharmaceutical company in creating about 100 new jobs at its Dortmund site.

Boehringer Ingelheim member of the Board of Managing Directors Dr Wolfgang Baiker said: "The Respimat inhaler will also in future be the inhalation device for applying our respiratory medications."

Manufacturing of the Respimat inhaler for the global market is carried out by the Boehringer Ingelheim microParts in Dortmund.

In September 2004, the company acquired the microtechnology company STEAG microParts and integrated it into the group.

The Respimat inhalers are filled with the relevant active pharmaceutical ingredients at the company headquarters in Ingelheim and then distributed worldwide.

At Ingelheim, the company is investing an additional €72m in the expansion of the Respimat production.

The company said that without using propellants, the Respimat inhaler generates a long-lasting fine mist that transports the active ingredient to the user’s lungs.


Image: The new assembly line of the Respimat production. Photo: courtesy of Boehringer Ingelheim GmbH.